FluoroPharma Medical, Inc. announced the presentation of data from an ongoing Phase II clinical trial for (18) F-FCPHA (CardioPET) to assess myocardial perfusion and fatty acid uptake in coronary artery disease (CAD) patients. Dr. Fabian Demeure, author of the abstract on the clinical trial, presented the data at the SNMMI Winter Meeting on February 6(th). The results are very encouraging for fatty acid imaging.

(18) F-FCPHA was well tolerated and administered safely in study subjects at UC Louvain, part of a multi-center study in Belgium. (18) F FCPHA demonstrated rapid blood clearance with excellent image quality and image time was optimal; as early as 3 minutes post injection.